Single-use plastic is a topic that receives a lot of attention in the press and has catalyzed efforts to reduce the amount that is found in the ocean. Although the bulk of this pollution comes from consumer waste, the growing use of plastic in laboratories and biopharma manufacturing has not gone unnoticed. It has been estimated that 5.5 million tons of plastic waste is being generated globally for scientific research. In biopharma manufacturing, the utilization of single-use technologies (SUT) is said to be increasing by 20-24% each year.
Wrapping up our bioprocessing category is MilliporeSigma’s Biopharma Product Recycling Program. The increase in single-use plastics waste is pushing biopharma manufacturers to address the environmental impact of currently utilized methods of disposal, such as landfilling and incineration, and question whether there is a better option.
As single-use technology becomes mainstream, biopharma companies need a better way to handle waste
MilliporeSigma estimates that a single biopharma site produces about 12.5 tons waste per month that is eligible for recycling. As a leading supplier of single-use biopharmaceutical products, including single-use bags, tubing, connectors and filters, MilliporeSigma recognizes the need to reduce the environmental impact of its products.
In 2015, MilliporeSigma launched an exclusive partnership with Triumvirate Environmental in order to enable bioprocess manufacturing customers to fully recycle plastic single-use and disposable products.
MilliporeSigma is urging industry to recycle single-use technologies, which can be made into speed bumps, parking bollards, and plastic palettes.
By Flora Southey
The Biopharma Single-use Product Recycling Program - a collaboration between MilliporeSigma and Triumvirate Environmental - collects, shreds, sterillises and recycles disposable plastics for the biopharmaceutical industry.
The program has facilitated the recycling of single-use bags, tubing and connectors, and cartridge and capsule filters at Triumvirate's plant in Pennsylvania since 2015.
Biopharma leader celebrates the opening of a new child development center, continuing the company’s strategy to provide an energizing workplace enabling employees to balance work/life to achieve success at work and home
LAWRENCE, N.J., November. 3, 2017 -- Most mornings Jodi Thrasher drops her two pre-school children off at the new, state-of-the-art, Bristol-Myers Squibb Child Development Center in the new campus on Princeton Pike in Lawrence Township, N.J., before reporting to work. Jodi is the Strategy and Operations Lead at the company and knowing her kids are safe, in an onsite learning environment, enables her to focus on her work – helping deliver life-saving and enhancing medicines to patients with serious diseases.